20 Preemptive CMVIG treatment in patients with moderate hypogammaglobulinemia showed a trend to fewer rejection episodes in a randomized trial. 22 However, 1 small randomized trial found no difference in the rate of rejection between patients given CMVIG versus IV ganciclovir, both as preemptive therapy. 23 Anti-CMV strategies may also indirectly lower the risk for rejection by reducing CMV event rates.
← all excerpts
Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation.
1
—
—